Captopril in cardiological patients treatment: is there still place for the “first of the Mohicans”?

Cover Page

Cite item

Full Text

Abstract

Aim. To demonstrate significance and relevancy of the first angiotensin-converting enzyme inhibitor (ACE inhibitor) captopril use in treatment of patients with cardiovascular disorders. Materials and methods. The article covers the issues of captopril use launch, results of the main randomized clinical studies of it, basic pharmacokinetic characteristics, and indications for captopril use from the perspective of the present clinical guidelines. Conclusion. The first oral ACE inhibitor captopril that was developed more than 40 years ago still holds a valuable place in treatment of cardiovascular diseases such as arterial hypertension, myocardial infarction, congestive heart failure and diabetes mellitus complications. Despite development of ACE inhibitors with longer duration of action and new properties, captopril still remains one of the most effective medications with a wide range of clinical use - from uncomplicated hypertensive crises arrest to long-term use in patients with arterial hypertension, diabetes mellitus, and congestive heart failure. Captopril remains one of the few ACE inhibitors that have changed approaches to treatment of patients with heart failure and improved the survival rate of patients after acute myocardial infarction.

About the authors

Farogat Yu. Valikulova

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Email: mumtos1951@list.ru
Cand. Sci. (Med.), Assistant Professor at Department of Internal Medicine 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation

Liubov Yu. Koroleva

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Cand. Sci. (Med.), Assistant Professor 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation

Olesia V. Melnichenko

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Cand. Sci. (Med.), Assistant Professor 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation

Elena M. Duryndina

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Cand. Sci. (Med.), Assistant Professor 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation

Fazliniso N. Muradova

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

student 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation

Mariia M. Alekseeva

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

student 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation

References

  1. Cushman D.W, Ondetti M.A. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991; 17: 589-92.
  2. Smith C.G, Vane J.R. The discovery of captopril. FASEB Jounal 2003; 17: 788-9.
  3. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management: is nice always good? J Hypertens 2012; 30: 660-8.
  4. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6-31. doi: 10.26442/2075082X.2019.1.190179
  5. Терпигорев С.А., Никишенков А.М., Кабанова Т.Г. и др. Применение каптоприла в лечении сердечно-сосудистых заболеваний. Consilium Medicum. 2018; 20 (1): 21-6.
  6. Hansson L, Lindholm L.H et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
  7. Приказ Минздрава России №549н от 07.08.2013 «Об утверждении требований к комплектации лекарственными препаратами и медицинскими изделиями укладок и наборов для оказания скорой медицинской помощи».
  8. Mansoor G.A, Frishman W.H. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis 2002; 4: 358-71.
  9. Мареев В.Ю., Фомин И.В. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (S6).
  10. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273 (18): 1450-6.
  11. Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. Влияние терапии на прогноз и выживаемость больных с хронической сердечной недостаточностью. Рус. мед. журн. 1999; 2: 9.
  12. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
  13. Pitt B, Poole-Wilson P.A, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
  14. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752-60.
  15. Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8.
  16. Pfeffer M.A, McMurray J.J.V, Velazquez E.J et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20): 1893-906. doi: 10.1056/NEJMoa032292
  17. Progress. Effects of a Perindopril-Based Blood Pressure-Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease: A Randomized Controlled Trial. Stroke 2003; 34 (10): 2333-8. DOI:10.1161 / 01. STR. 0000091397.81767.40

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies